anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Buprenorphine
Trial phase: Phase 2 | Phase 3
ATC code: N02AE01 | N07BC01 | N07BC51
SMILES: COC12CCC3(CC1C(C)(O)C(C)(C)C)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)C2O5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Buprenorphine Observed in office induction

Buprenorphine: Dose is determined according to the participants' individual need.
Eligibility criteria:
Inclusion Criteria:

DSM-IV criteria for current opioid dependence with physical dependence and are seeking treatment
Recent opioid use
Individuals must describe opioids as their primary drug of abuse.
18-65 years of age
Able to give informed consent and comply with study procedures
Financially able to receive treatment at AIM and obtain medication (e.g., Medicaid)

Exclusion Criteria:

DSM-IV opioid dependence without physical dependence
Any current Axis I psychiatric disorder(s) as defined by DSM-IV-TR that in the investigator's judgment are unstable or would be disrupted by study participation (e.g., psychosis, active suicidal or homicidal ideation).
Individuals who are significant risk for suicide based on their current mental state or history.
DSM-IV alcohol or benzodiazepine dependence with physiologic dependence.
Pregnancy, lactation. Women must also agree to use a method of contraception with proven efficacy and agree not to become pregnant during the study.
Unstable physical disorder that might make participation hazardous.
Individuals with a known allergy, sensitivity or adverse reaction to buprenorphine.
Past life-threatening idiosyncratic severe opioid withdrawal reaction (e.g., psychosis, seizure)
Current buprenorphine maintenance
Current long-acting opioid use (e.g., methadone)
Inability to read or understand the self-report assessment forms unaided
Intervention: Zolpidem Tartrate
Trial phase: Phase 1
SMILES: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 34
Group description: All subjects received each of the two study regimens in a randomly assigned sequence of dosing periods. On the mornings of Day 1 and Day 8, each subject received one tablet of either zolpidem tartrate 10 mg or Ambien® 10 mg following an overnight fast.
Eligibility criteria:
Inclusion Criteria:

Sex: Male or Female; similar proportions of each preferred
Age: At least 18 years
Weight: must be 15% of ideal weight for height and frame
Subjects must be in good health and physical condition as determined by medical history
Subjects must read and sign the Consent Form

Exclusion Criteria:

History of treatment for alcoholism, substance abuse, or drug abuse within past 24 months.
History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
History of GERD, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease.
History of treatment for asthma within the past five (5) years.
History of mental depression.
History of pulmonary disease.
History of sleep apnea.
Females who are pregnant or lactating.
History of hypersensitivity to zolpidem tartrate, or any hypnotic or sedative.
Treatment with any other investigational drug during the four weeks prior to the initial dosing of the study.
Donation of blood within four weeks prior to the initial dosing of the study
Smokers or subjects who use tobacco/nicotine products. Three months abstinence is required.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
Eligibility criteria:
Inclusion Criteria:

Age >45
Ability to make follow-up visits over the 6 month protocol
Ability to give informed consent
Eaton grade 2-3 thumb carpo-metacarpal joint osteoarthritis with pain over 3/10 on visual analogue scale with symptoms present greater then 6 months.

Exclusion Criteria:

Recent trauma to the hand or wrist or fractures eeen on radiographs
Eaton grade 1, or 4 joints affected
Metabolic bone disease
Recent systemic or localized infection (within last 2 weeks)
History of rheumatologic disease
Allergies to injected solutions
Thumb carpo-metacarpal joint injections in the prior 6 months.
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Lidocaine patch One patch is changed every twenty-four hours
Eligibility criteria:
Inclusion Criteria:

Adult women >18 years who develop neuropathic pain in the breast scar area and/or ipsilateral arm following breast cancer surgery
Has a healed incision(s)
Has no recurrent disease in the painful area
Is able to read, write and understand English

Exclusion Criteria:

Presence of another type of pain that is more severe than the neuropathic pain
Use of an opioid analgesic of greater than 60 mg codeine/day
Is actively trying to become pregnant
Has a medical contraindication to the use of lidocaine
Has an allergy to lidocaine
Is taking a coanalgesic for neuropathic pain.
Intervention: Prednisone acetate
Trial phase: Phase 2
SMILES: [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: immediate release prednisone
Eligibility criteria:
Inclusion Criteria:

The subject must be able to understand the terms of the written informed consent form, and must provide a dated and signed form before the start of any study procedure
At least 18 years old
Patient having a diagnosis of asthma dating back more than 6 months at the time of inclusion
Asthma necessitating a continuous treatment by oral corticoids
A minimum of 3 nocturnal awakenings due to asthma during the last screening week
Stable dose of oral glucocorticoids for at least 4 weeks prior to inclusion into the study
No change in asthma medication during the last 4 weeks prior to V0
Non-smoker or ex-smoker (having stopped smoking more than one year previously and with a smoking history of less than 10 pack years )
Female patients of childbearing potential must be using a medically accepted contraceptive regimen
Able to perform the required study procedures including handling of medication containers and diaries

Exclusion Criteria:

Poorly controlled asthma, defined as meeting at least one of the following within the 4 weeks prior to Visit V0:

hospital admission for asthma (including treatment in an emergency room),
a lower airway infection,
Diagnosis of chronic obstructive pulmonary disease or other relevant lung diseases (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, active tuberculosis, interstitial lung disease)
Clinically significant abnormalities of the hematological or biochemical constants
Pregnancy or breastfeeding
Participation in another clinical study within 30 days preceding Visit V0,
Re-entry of patients previously enrolled in this trial,
Suspected inability or unwillingness to comply with the study procedures
Alcohol or drug abuse
Need to take a non-authorised concomitant treatment (cf. list of medicaments not authorised during the study) in the course of the study
Other disease requiring treatment with corticosteroids
Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
Patient with a hospitalisation scheduled during the study period
Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension, etc.)
Intervention: Sitagliptin
Trial phase: Phase 4
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 108
Group description: Sitagliptin 100 mg once daily
Eligibility criteria:
Inclusion Criteria:

Male or female, age 18-75
Type 2 diabetes
At least 3 months of treatment with maximum tolerated doses of metformin and a sulfonylurea agent, and inadequate glycemic control (Hemoglobin A1c (HbA1c) >7.0%)
Able to comply with all scheduled visits and requirements of the protocol

Exclusion Criteria:

Any contraindications to the use of metformin or a sulfonylurea agent
Extreme hyperglycemia or symptoms of polyuria or polydipsia
Current or previous chronic use of insulin (other than for treatment of gestational diabetes)
History of confirmed (or clinical suspicion of) type 1 diabetes mellitus
Episodes of symptomatic hypoglycemia averaging greater than once per day
Estimated glomerular filtration rate (eGFR) < 60 mL/min
Subjects with active hemolytic anemias or hemoglobin variants that render the measurement of HbA1c unreliable
History of any clinically significant hepatic, cardiovascular (including the use of digoxin), or other major systemic disease that may make the use of sitagliptin unsafe, or otherwise make the interpretation of the data difficult.
Female subjects of childbearing potential who are sexually active and not using a reliable form of contraception
Current pregnancy or lactation.
Subjects who will likely require or initiate therapy with drugs that may interfere with glucose metabolism during the course of the study.
Subjects who are in another investigational study or have received another investigational medication within 30 days of study entry
Subjects who are unable or unwilling to give informed consent, comply with all components of the study protocol, attend all scheduled follow-up visits, or present other barriers that would make the implementation of the protocol unusually difficult.
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Dexamethasone : Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
Eligibility criteria:
Inclusion Criteria:

Patients with oral chronic graft-versus-host disease
Patients 4 years of age or older
Stable cGVHD medication regimen for the four weeks prior to study enrollment

Exclusion Criteria:

Patients already on topical steroid or tacrolimus therapies
Intervention: Tacrolimus
Trial phase: Phase 2
ATC code: D11AH01 | L04AD02
SMILES: C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Tacrolimus Arm Closed to Accrual as of January 2012

Tacrolimus : Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
Eligibility criteria:
Inclusion Criteria:

Patients with oral chronic graft-versus-host disease
Patients 4 years of age or older
Stable cGVHD medication regimen for the four weeks prior to study enrollment

Exclusion Criteria:

Patients already on topical steroid or tacrolimus therapies
Intervention: Glucagon-like peptide 1
Trial phase: Phase 2
SMILES: CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(N)=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.

GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
Eligibility criteria:
Inclusion Criteria:

Male and female volunteers 21-65 years.
BMI > 40.
Preoperative hematocrit level of at least 34% for women and 38% for men.
Postoperative hematocrit level of at least 34% for women and 36% for men.

Exclusion Criteria:

Volunteers whose hematocrit level does not meet the above criteria.
Pregnant and or lactating females.
Intervention: Pavinetant
Trial phase: Phase 2
SMILES: CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: AZD2624 40 mg
Eligibility criteria:
Inclusion Criteria:

Females of non-childbearing potential
Diagnosis of Schizophrenia

Exclusion Criteria:

Clinically relevant disease and /or abnormalities.
Alcohol or substance abuse not in remission
Enrollment in another investigational study within 30 days
Intervention: Olanzapine
Trial phase: Phase 2
ATC code: N05AH03 | N05AH53
SMILES: Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Olanzapine 15 mg
Eligibility criteria:
Inclusion Criteria:

Females of non-childbearing potential
Diagnosis of Schizophrenia

Exclusion Criteria:

Clinically relevant disease and /or abnormalities.
Alcohol or substance abuse not in remission
Enrollment in another investigational study within 30 days
Intervention: Tamoxifen
Trial phase: Phase 3
ATC code: L02BA01
SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Sex: Female
Age groups: Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1498
Group description: Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.

tamoxifen: oral tamoxifen plus placebo daily for 5 years
Eligibility criteria:
Inclusion Criteria:

Women enrolled in STAR trial at a site participating in Co-STAR
65 years of age or older
Have been randomized into STAR but have not started taking the study drug OR enrolled in STAR for a minimum of one year
Have not been diagnosed with dementia
Have signed a separate consent document for the Co-STAR Study
Previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors for this study

Exclusion Criteria:

Not enrolled in the STAR Trial
Younger than 65 years of age
Diagnosed with dementia
Intervention: Bupropion
Trial phase: Phase 2
ATC code: A08AA62 | N06AX12
SMILES: CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Subjects received bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.

Bupropion: 150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
Eligibility criteria:
Inclusion Criteria:

Must have a DSM-IV diagnosis of methamphetamine dependence as determined by MINI
Must have at least 1 amphetamine or methamphetamine positive urine specimen after the start of screening and before randomization or provide information to verify recent use if a positive urine sample can't be obtained
Must report using methamphetamine for 29 days or less during the 30 day period prior signing consent using the timeline follow-back method
Must be willing and able to comply with study procedures
Must be able to verbalize and understand consent forms and provide written informed consent
Must be seeking treatment for methamphetamine dependence

Exclusion Criteria:

Please contact study site for more information
Intervention: Leuprolide Acetate
Trial phase: Phase 3
SMILES: CC(=O)O.CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: GnRH agonist + placebo

leuprolide acetate: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
Eligibility criteria:
Inclusion Criteria:

Healthy premenopausal women, aged 18 to 49 years
Regular menses (no missed cycles in previous year; cycle length 25-35 days)
Positive luteinizing hormone test or a mid-luteal serum progesterone greater than 3 ng/mL
Nonsmokers
Willing to receive all study interventions
Physically able and willing to be randomized to participate in a supervised resistance exercise training program

Exclusion Criteria:

Already performing high-intensity resistance exercise training more than 1 day per week
On diabetes medications
Use of hormonal contraception in the past 3 months
On oral or inhaled glucocorticoids
Positive pregnancy test
Intention to become pregnant or start hormonal contraceptive therapy during the period of study
Lactation
Hypersensitivity to extrinsic peptide hormones, mannitol, Gonadotropin-releasing hormone (GnRH), leuprolide acetate, benzyl alcohol (the vehicle for injection of leuprolide acetate), or transdermal patch
Score greater than 16 on the Center for Epidemiologic Studies Depression Scale and Beck Depression Inventory-II score greater than 18, or clinician recommendation to exclude
Severe osteopenia or osteoporosis (proximal femur or lumbar spine t scores < -2.0)
BMI greater than 40 kg/m2, weight change of more than ± 2 kg in last 6 months, or weight-reduced by more than 5 kg from maximal body weight
Abnormal vaginal bleeding
History of breast cancer or other estrogen-dependent neoplasms
History of venous thromboembolic events
Moderate or severe renal impairment (creatinine clearance <50 mL/min by Cockcroft-Gault)
Chronic hepatobiliary disease, defined as liver function tests (AST, ALT, alkaline phosphatase, total bilirubin) greater than 1.5 times the upper limit of normal
Thyroid dysfunction, defined as ultra sensitive TSH less than 0.5 or greater than 5.0 mU/L
Uncontrolled hypertension, defined as resting BP greater than 150/90 mmHg
Cardiovascular disease, including indicators of ischemic heart disease or serious arrhythmias at rest or during the graded exercise test; follow-up diagnostic testing to rule out cardiovascular disease by a cardiologist will be allowed
Orthopedic or other problems that would interfere with participation in the exercise program
Intervention: Acamprosate
Trial phase: Phase 4
ATC code: N07BB03
SMILES: CC(=O)NCCCS(=O)(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 36
Group description: All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.

Acamprosate: Acamprosate 333mg, ii tablets PO tid x 2 weeks
Eligibility criteria:
Inclusion Criteria:

DSM-IV diagnosis of schizophrenia/schizoaffective disorder
Age 18-55 years
Male or female
Any Race/ethnicity
Participants will be analyzed separately depending on whether they do or do not have a history of an alcohol use disorder

Exclusion Criteria:

Pregnant/nursing females or females not using adequate birth control
Documented history of mental retardation/severe neurological disorder/head injury with loss of consciousness
DSM-IV diagnosis of substance dependence in previous six months/abuse in the previous three months (except nicotine)
Serious suicidal risk in the previous six months
History of renal failure/creatinine clearance of less than 50mL/min
Current treatment with clozapine
Contraindication to MRI scanning.
Intervention: Ethanol
Trial phase: Phase 3
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 476
Group description: Clindamycin 1% as clindamycin phosphate and tretinoin 0.025% (CT) applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Male or female 12 years of age or older in good general health
Investigator's Static Global Assessment (ISGA) score of 2 or greater at Baseline

Exclusion Criteria:

Any nodulo-cystic lesions at Baseline
Pregnancy or breast feeding
History or presence of regional enteritis or inflammatory bowel disease or similar symptoms.
Treatment with estrogens, including oral, implanted and topical contraceptives, androgens, or anti-androgenic agents for 12 weeks or less prior to study start.
Use of topical anti-acne medications within the past 2 weeks.
Use of topical or systemic antibiotics on the face within the past 2 weeks.
Use of topical or systemic corticosteroids within the past 2 weeks.
Use of systemic retinoids within the past 3 months.
Use of astringents, toners and skin cleansers for less than 2 weeks prior to the start of the study.
Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
Concomitant use of mega-doses of certain vitamins, such as vitamin D (>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.
Concomitant use of tanning booths or sunbathing.
Known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, retinoids or excipients of the study product
A significant medical history of or are currently immunocompromised
Current drug or alcohol abuse. (Drug screening not required.)
Use of any investigational therapy within 4 weeks of enrollment.
Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.
Intervention: Ondansetron
Trial phase: Phase 2
ATC code: A04AA01
SMILES: Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy

Ondansetron: 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
Eligibility criteria:
Inclusion Criteria:

Males and females who have given written informed consent.
Ages 18 years and above and, must weigh at least 40 Kg and no more than 140 Kg.
Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters.
Current DSM-IV diagnosis of cocaine dependence.
At least one positive urine drug screen for cocaine at screen or baseline prior to randomization.
The pregnancy test for females at intake must be negative.
Literacy in English and ability to read, understand, and complete the ratings scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments.
Answered an advertisement in the newspaper/radio/television, and expressing a wish to stop using cocaine.
Willing to participate in behavioral treatments for cocaine dependence.

Exclusion Criteria:

Please contact site for additional information